AEON Biopharma Net Income Growth & History (AEON)
AEON Biopharma's net income was −$39.2M for fiscal 2025.
View full AEON Biopharma company overviewAEON Biopharma annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$39.2M | −$81.2M | — |
| 2024 | 2024-12-31 | $42.0M | $366.0M | — |
| 2023 | 2023-12-31 | −$324.0M | −$271.4M | — |
| 2022 | 2022-12-31 | −$52.6M | −$60.8M | — |
| 2021 | 2021-12-31 | $8.2M | — | — |
AEON Biopharma quarterly net income
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$1.2M | $5.5M | — |
| Q1 2026 | 2026-03-31 | −$11.8M | −$20.9M | — |
| Q4 2025 | 2025-12-31 | −$37.1M | −$39.2M | — |
| Q3 2025 | 2025-09-30 | −$4.5M | $1.6M | — |
| Q2 2025 | 2025-06-30 | −$6.6M | −$170.8M | — |
| Q1 2025 | 2025-03-31 | $9.1M | $127.1M | — |
| Q4 2024 | 2024-12-31 | $2.1M | — | — |
| Q3 2024 | 2024-09-30 | −$6.2M | $291.5M | — |
| Q2 2024 | 2024-06-30 | $164.1M | — | — |
| Q1 2024 | 2024-03-31 | −$118.0M | −$100.4M | — |
| Q3 2023 | 2023-09-30 | −$297.7M | −$287.3M | — |
| Q2 2023 · Jul 21 | 2023-07-21 | −$27.7M | −$29.5M | — |
| Q2 2023 · Jun 30 | 2023-06-30 | −$15.4M | −$17.2M | — |
| Q1 2023 | 2023-03-31 | −$17.6M | −$20.4M | — |
| Q4 2022 | 2022-12-31 | −$46.8M | −$47.0M | — |
| Q3 2022 | 2022-09-30 | −$10.4M | −$16.1M | — |
| Q2 2022 | 2022-06-30 | $1.9M | $5.9M | — |
| Q1 2022 | 2022-03-31 | $2.8M | −$3.5M | −56.11% |
| Q4 2021 | 2021-12-31 | $247,873 | — | — |
| Q3 2021 | 2021-09-30 | $5.7M | — | — |
| Q2 2021 | 2021-06-30 | −$4.0M | — | — |
| Q1 2021 | 2021-03-31 | $6.3M | — | — |
AEON Biopharma net income trends
Between the periods ended 2021-12-31 and 2025-12-31, AEON Biopharma's net income decreased from $8.2M to −$39.2M, a change of −$47.4M. The latest reported quarter, Q2 2026, shows −$1.2M.
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AEON Biopharma source filings ↗